Role of Advanced Glycation End Products in Hypertension and Atherosclerosis: Therapeutic Implications

被引:0
|
作者
Sudesh Vasdev
Vicki Gill
Pawan Singal
机构
[1] Memorial University of Newfoundland,Discipline of Medicine, Faculty of Medicine, Room H
[2] University of Manitoba,4310, Health Sciences Centre
来源
关键词
Hypertension; Atherosclerosis; Advanced glycation end products; Insulin resistance; Oxidative stress; Inflammation;
D O I
暂无
中图分类号
学科分类号
摘要
The vascular diseases, hypertension and atherosclerosis, affect millions of individuals worldwide, and account for a large number of deaths globally. A better understanding of the mechanism of these conditions will lead to more specific and effective therapies. Hypertension and atherosclerosis are both characterized by insulin resistance, and we suggest that this plays a major role in their etiology. The cause of insulin resistance is not known, but may be a result of a combination of genetic and lifestyle factors. In insulin resistance, alterations in glucose and lipid metabolism lead to the production of excess aldehydes including glyoxal and methylglyoxal. These aldehydes react non-enzymatically with free amino and sulfhydryl groups of amino acids of proteins to form stable conjugates called advanced glycation end products (AGEs). AGEs act directly, as well as via receptors to alter the function of many intra- and extracellular proteins including antioxidant and metabolic enzymes, calcium channels, lipoproteins, and transcriptional and structural proteins. This results in endothelial dysfunction, inflammation and oxidative stress. All these changes are characteristic of hypertension and atherosclerosis. Human and animal studies have demonstrated that increased AGEs are also associated with these conditions. A pathological role for AGEs is substantiated by studies showing that therapies that attenuate insulin resistance and/or lower AGEs, are effective in decreasing oxidative stress, lowering blood pressure, and attenuating atherosclerotic vascular changes. These interventions include lipoic acid and other antioxidants, AGE breakers or soluble receptors of AGEs, and aldehyde-binding agents like cysteine. Such therapies may offer alternative specific means to treat hypertension and atherosclerosis. An adjunct therapy may be to implement lifestyle changes such as weight reduction, regular exercise, smoking cessation, and increasing dietary intake of fruits and vegetables that also decrease insulin resistance as well as oxidative stress.
引用
收藏
页码:48 / 63
页数:15
相关论文
共 50 条
  • [41] Critical Role for the Advanced Glycation End-Products Receptor in Pulmonary Arterial Hypertension Etiology
    Meloche, Jolyane
    Courchesne, Antony
    Barrier, Marjorie
    Carter, Sophie
    Bisserier, Malik
    Paulin, Roxane
    Lauzon-Joset, Jean-Francois
    Breuils-Bonnet, Sandra
    Tremblay, Eve
    Biardel, Sabrina
    Racine, Christine
    Courture, Christian
    Bonnet, Pierre
    Majka, Susan M.
    Deshaies, Yves
    Picard, Frederic
    Provencher, Steeve
    Bonnet, Sebastien
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2013, 2 (01):
  • [42] Uncovering the role of circulating soluble receptor for advanced glycation end products in hypertension: relationships with albuminuria
    Tsioufis, C.
    Dimitriadis, K.
    Syrseloudis, D.
    Thomopoulos, C.
    Mazaraki, A.
    Tolis, P.
    Sideris, S.
    Stefanadi, E.
    Kallikazaros, I.
    Stefanadis, C.
    EUROPEAN HEART JOURNAL, 2009, 30 : 582 - 582
  • [43] Role of advanced glycation end products in diabetic vascular injury: molecular mechanisms and therapeutic perspectives
    Jing Liu
    Shuo Pan
    Xiqiang Wang
    Zhongwei Liu
    Yong Zhang
    European Journal of Medical Research, 28
  • [44] Role of advanced glycation end products in diabetic vascular injury: molecular mechanisms and therapeutic perspectives
    Liu, Jing
    Pan, Shuo
    Wang, Xiqiang
    Liu, Zhongwei
    Zhang, Yong
    EUROPEAN JOURNAL OF MEDICAL RESEARCH, 2023, 28 (01)
  • [45] Receptor for advanced glycation end products in bacterial infection: is there a role for immune modulation of receptor for advanced glycation end products in the treatment of sepsis?
    Christaki, Eirini
    Lazaridis, Nikolaos
    Opal, Steven M.
    CURRENT OPINION IN INFECTIOUS DISEASES, 2012, 25 (03) : 304 - 311
  • [46] Advanced glycation end products (AGE)-modified proteins and their potential relevance to atherosclerosis
    Horiuchi, S
    TRENDS IN CARDIOVASCULAR MEDICINE, 1996, 6 (05) : 163 - 168
  • [47] ADVANCED GLYCATION END PRODUCTS ACCELERATE ATHEROSCLEROSIS VIA ENHANCEMENT OF OXIDATIVE STRESS
    Hou, Fan Fan
    Zhang, Wei Ru
    Liu, Shang Xi
    Guo, Zhi Jian
    Zhou, Zhan Mei
    Wang, Guo Bao
    Fu, Ning
    Liu, Zhi Qiang
    Wang, Li
    Zhou, Mei
    NEPHROLOGY, 2005, 10 : A119 - A120
  • [48] THE ROLE OF ADVANCED GLYCATION END PRODUCTS IN PATOGENESIS OF DIABETIC NEPHROPATHY
    Gavrilova, Alina O.
    Severina, Anastasia S.
    Shamhalova, Minara S.
    Shestakova, Marina, V
    DIABETES MELLITUS, 2021, 24 (05): : 461 - 469
  • [49] The Role of Advanced Glycation End Products in Diabetic Vascular Complications
    Rhee, Sang Youl
    Kim, Young Seol
    DIABETES & METABOLISM JOURNAL, 2018, 42 (03) : 188 - 195
  • [50] Role of the receptor for advanced glycation end products in hepatic fibrosis
    Lohwasser, Christina
    Neureiter, Daniel
    Popov, Yury
    Bauer, Michael
    Schuppan, Detlef
    WORLD JOURNAL OF GASTROENTEROLOGY, 2009, 15 (46) : 5789 - 5798